Investment Thesis
Strong revenue growth (+128% YoY) and pristine balance sheet with zero debt are offset by severe earnings quality concerns: the $178M gap between reported net income ($169.7M) and negative operating cash flow (-$8.1M) indicates non-recurring items are inflating profitability, while the 94.7% net margin is extraordinarily high for pharma and unsustainable.
Strengths
- Exceptional revenue growth of 128% YoY indicating strong commercial momentum
- Pristine balance sheet with zero long-term debt and $260.2M stockholders equity
- Exceptional ROE (65.2%) and ROA (61.2%) on reported earnings basis
Risks
- Severe earnings quality concerns: $178M divergence between net income and operating cash flow indicates non-cash gains, milestone payments, or deferred revenue are inflating profits
- Extraordinarily high profit margins (94.7% net, 94.3% operating) are unsustainable for pharma and likely driven by one-time items
- Negative operating cash flow with only $23.7M cash balance creates sustainability risk despite apparent profitability
Key Metrics to Watch
- Operating cash flow trend and underlying drivers of net income to assess earnings quality
- Breakdown of revenue by source (product sales vs. milestone payments vs. licensing) to identify recurring vs. non-recurring
- Cash position trajectory and burn rate given negative OCF despite reported profitability
Financial Metrics
Revenue
179.1M
Net Income
169.7M
EPS (Diluted)
$0.87
Free Cash Flow
-8.1M
Total Assets
277.2M
Cash
23.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
94.3%
Net Margin
94.7%
ROE
65.2%
ROA
61.2%
FCF Margin
-4.5%
Balance Sheet & Liquidity
Current Ratio
54.26x
Quick Ratio
54.26x
Debt/Equity
0.00x
Debt/Assets
6.1%
Interest Coverage
2,165.49x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:28:31.598138 |
Data as of: 2026-03-31 |
Powered by Claude AI